Logo

Agilent Expects 2- to 5-Percent Decline in Q3 Revenue; Closes Stratagene Buy

Jun 07, 2007
NEW YORK (GenomeWeb News) — Agilent Technologies today said it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, or to between $1.38 billion and $1.42 billion from $1.45 billion last year.
 
The company also said it has closed its acquisition of Stratagene for $10.94 a share, or $246 million.
 
Agilent said Stratagene has more than 450 employees, who have now joined the firm. The company did not mention trimming Stratagene’s workforce.
 
Stratagene has operations in Texas, California, Japan, and Amsterdam.
Breaking News
The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.